低甲基化药物联合纳武利尤单抗治疗异基因造血细胞移植后急性髓系白血病复发的II期试验——免疫特征与缓解相关
该前瞻性、II期、开放标签、单臂研究纳入16例异基因造血细胞移植后血液学复发的急性髓系白血病患者,接受低甲基化药物联合抗PD-1抗体纳武利尤单抗治疗。第42天总缓解率(完全缓解/部分缓解)为25%,另25%患者达疾病稳定,中位总生存期15.6个月。高参数流式细胞术显示缓解者中活化(ICOS+、HLA-DR+)、低衰老(KLRG1-、CD57-)的CD8+效应T细胞频率更高,并在临床前模型中验证。
要点
- 移植后血液学复发AML接受HMA联合纳武利尤单抗,第42天CR/PR率为25%。
- 另25%患者达疾病稳定,中位总生存期15.6个月。
- 缓解者活化低衰老CD8+效应T细胞频率更高,单细胞转录组示促炎重编程。
核心结论
- 移植后HMA/纳武利尤单抗联合方案在部分患者中诱导抗AML免疫应答,作者认为可考虑作为第二次异基因造血细胞移植的桥接方案。
研究设计与样本
- 前瞻性、II期、开放标签、单臂研究,纳入16例异基因造血细胞移植后血液学复发的急性髓系白血病患者。
- 患者接受低甲基化药物联合抗PD-1抗体纳武利尤单抗,中位纳武利尤单抗应用次数为2次(范围1-7次)。
- 采用基于DNA、RNA和蛋白质的单细胞技术评估缓解相关生物标志物,并在临床前模型中验证。
- 试验注册号:EudraCT-No. 2017-002194-18。
主要发现
- 第42天总缓解率(完全缓解/部分缓解)为25%,另25%的患者达疾病稳定。
- 中位总生存期为15.6个月。
- 高参数流式细胞术显示缓解者中活化(ICOS+、HLA-DR+)、低衰老(KLRG1-、CD57-)的CD8+效应T细胞频率更高。
- 单细胞转录组学显示缓解者中T细胞和髓系细胞表达谱出现促炎性重编程。
临床怎么用
- 作者认为,移植后HMA/纳武利尤单抗联合方案在部分患者中诱导抗AML免疫应答,可考虑作为第二次异基因造血细胞移植的桥接方案。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute myeloid leukaemia (AML) relapse after allogeneic haematopoietic cell transplantation (allo-HCT) is often driven by immune-related mechanisms and associated with poor prognosis. Immune checkpoint inhibitors combined with hypomethylating agents (HMA) may restore or enhance the graft-versus-leukaemia effect. Still, data about using this combination regimen after allo-HCT are limited. We conducted a prospective, phase II, open-label, single-arm study in which we treated patients with haematological AML relapse after allo-HCT with HMA plus the anti-PD-1 antibody nivolumab. The response was correlated with DNA-, RNA- and protein-based single-cell technology assessments to identify biomarkers associated with therapeutic efficacy. Sixteen patients received a median number of 2 (range 1-7) nivolumab applications. The overall response rate (CR/PR) at day 42 was 25%, and another 25% of the patients achieved stable disease. The median overall survival was 15.6 months. High-parametric cytometry documented a higher frequency of activated (ICOS+ , HLA-DR+ ), low senescence (KLRG1- , CD57- ) CD8+ effector T cells in responders. We confirmed these findings in a preclinical model. Single-cell transcriptomics revealed a pro-inflammatory rewiring of the expression profile of T and myeloid cells in responders. In summary, the study indicates that the post-allo-HCT HMA/nivolumab combination induces anti-AML immune responses in selected patients and could be considered as a bridging approach to a second allo-HCT. Trial-registration: EudraCT-No. 2017-002194-18.
引用
- Apostolova P, Kreutmair S, Toffalori C, et al. Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation-Immune signature correlates with response. Br J Haematol. 2023. PMID: 37539479. doi:10.1111/bjh.19007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。